MedPath

The Safety and Efficacy study of IVA technique Combined Stem Cell Therapy (IVASc) in Patients With Premature Ovarian Failure (POF)

Phase 1
Conditions
Premature Ovarian Failure (POF).
Primary ovarian failure
E28.3
Registration Number
IRCT20211021052828N1
Lead Sponsor
Mehr medical Institute
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Female
Target Recruitment
10
Inclusion Criteria

Normal karyotyping female
Diagnosed with Premature Ovarian Failure: Serum FSH > 20 IU/l, AMH < 0.3 ng /mL
Normal TSH
Agree to sign the designed consent for the study
women aged 18 to 40 years old

Exclusion Criteria

Thyroid dysfunction
Immunological Conditions
Past history of malignancy/cemotherapy/radiotherapy
Infectious diseases: HIV+, hepatitis B+, C+
Abnormal karyotype
Previous surgical management of ovarian pathology
Severe endometriosis
Breast cancer, ovarian cancer
Severe pulmonary, kidney and hematological disease, diabetes (type I,II), ...
Severe anemia (Hemoglobin <8 g/dL)

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath